Streetbeat News

Price Targets

MBLY

Mobileye shares are trading lower after RBC Capital lowered its price target on the stock from $34 to $24.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:31 pm

WING

Stephens & Co. analyst Jim Salera has reiterated an Overweight rating on Wingstop (NASDAQ:WING) and maintained a price target of $475.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:20 pm

OUST

WestPark Capital analyst Kevin Garrigan maintains a Buy rating on Ouster (NYSE:OUST) but lowers the price target from $17 to $13.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:17 pm

CRWD

CrowdStrike Holdings, Inc. (NASDAQ:CRWD) shares are moving higher as the company prepares to release its quarterly fiscal earnings on August 28. Analysts estimate an EPS of 98 cents and revenue of $958.69 million. The company is also facing legal action from Delta Air Lines over a July 19 outage, which Delta claims caused $500 million in damages. Multiple analysts have recently adjusted their price targets for CrowdStrike.

Portfolio Pulse from Dylan Berman

August 14, 2024 | 6:16 pm

SVRA

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Savara (NASDAQ:SVRA) and maintained a $10 price target.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:15 pm

CCJ

GLJ Research analyst Gordon Johnson reiterates a Buy rating on Cameco (NYSE:CCJ) and maintains a price target of $63.73.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:13 pm

SBIG

WestPark Capital analyst Casey Ryan has reiterated a Buy rating on SpringBig Holdings (OTC:SBIG) and maintained a $1 price target.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:05 pm

ANAB

HC Wainwright & Co. analyst Emily Bodnar has reiterated a Buy rating on AnaptysBio (NASDAQ:ANAB) and maintained a price target of $55.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:03 pm

ZTS

Analysts have provided mixed ratings for Zoetis (NYSE:ZTS) in the latest quarter, with 3 bullish and 1 somewhat bullish ratings. The average 12-month price target has increased by 7.77% to $213.75. Key analysts have raised their price targets, reflecting positive sentiment.

Portfolio Pulse from Benzinga Insights

August 14, 2024 | 6:00 pm

STIM

JMP Securities analyst David Turkaly maintains a Market Outperform rating on Neuronetics (NASDAQ:STIM) but lowers the price target from $7 to $3.

Portfolio Pulse from Benzinga Newsdesk

August 14, 2024 | 6:00 pm